The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites

Parasitology

Volumn 131, Issue 1, 2005, Pages 37-44

  Lindenthal, C ^a   Weich, N ^b   Chia, Y S ^c   Heussler, V ^c   Klinkert, M Q ^c  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

Development inhibition; Plasmodium; Proteasome inhibitor MLN 273

Indexed keywords

MLN 273; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL DIVISION; CELL MATURATION; CHEMOTHERAPY; DRUG TARGETING; ENZYME ACTIVITY; ERYTHROCYTE; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; NONHUMAN; PLASMODIUM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCHIZONT; WESTERN BLOTTING;

ANIMALS; ANTIMALARIALS; ERYTHROCYTES; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROTEASOME ENDOPEPTIDASE COMPLEX;

EUKARYOTA; PLASMODIUM (APICOMPLEXA); PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM PARASITES;

EID: 22444449129     PISSN: 00311820     EISSN: None     Source Type: Journal    
DOI: 10.1017/S003118200500747X     Document Type: Article

References (25)

1. ADAMS, J., PALOMBELLA, V. J., SAUSVILLE, E. A., JOHNSON, J., DESTREE, A., LAZARUS, D. D., MAAS, J., PIEN, C. S., PRAKASH, S. & ELLIOTT, P. J. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research 59, 2615-2622.
2. AGHAJANIAN, C., SOIGNET, S., DIZON, D. S., PIEN, C. S., ADAMS, J., ELLIOTT, P. J., SABBATINI, P., MILLER, V., HENSLEY, M. L., PEZZULLI, S., CANALES, C., DAUD, A. & SPRIGGS, D. R. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research 8, 2505-2511.
3. BRATOSIN, D., ESTAQUIER, J., PETIT, F., ARNOULT, D., QUATANNENS, B., TISSIER, J. P., SLOMIANNY, C., SARTIAUX, C., ALONSO, C., HUART, J. J., MONTREUIL, J. & AMEISEN, J. C. (2001). Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death and Differentiation 8, 1143-1156.
4. DARWIN, K. H., EHRT, S., GUTIERREZ-RAMOS, J. C., WEICH, N. & NATHAN, C. F. (2003). The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302, 1963-1966.
5. DESAKORN, V., SILAMUT, K., ANGUS, B., SAHASSANANDA, D., CHOTIVANICH, K., SUNTHARASAMAI, P., SIMPSON, J. & WHITE, N. J. (1997). Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Transactions of the Royal Society for Tropical Medicine and Hygiene 91, 479-483.
6. ETLINGEN, J. D. & GOLDBERG, A. L. (1977). A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proceedings of the National Academy of Sciences, USA 74, 54-58.
7. GANTT, S. M., MYUNG, J. M., BRIONES, M. R., LI, W. D., COREY, E. J., OMURA, S., NUSSENZWEIG, V. & SINNIS, P. (1998). Proteasome inhibitors block development of Plasmodium spp. Antimicrobial Agents and Chemotherapy 42, 2731-2738.
8. GONZALEZ, J., BAI, G., FREVERT, U., COREY, E. J. & EICHINGER, D. (1999). Proteasome-dependent cyst formation and stage-specific ubiquitin mRNA accumulation in Entamoeba invadens. European Journal of Biochemistry 264, 897-904.
9. GONZALEZ, J., RAMALHO-PINTO, F. J., FREVERT, U., GHISO, J., TOMLINSON, S., SCHARFSTEIN, J., COREY, E. J. & NUSSENZWEIG, V. (1996). Proteasome activity is required for the stage-specific transformation of a protozoan parasite. Journal of Experimental Medicine 184, 1909-1918.
10. GRASSILLI, E., BENATTI, F., DANSI, P., GIAMMARIOLI, A. M., MALORNI, W., FRANCESCHI, C. & DESIDERIO, M. A. (1998). Inhibition of proteasome function prevents thymocyte apoptosis: involvement of ornithine decarboxylase. Biochemical and Biophysical Research Communications 250, 293-297.
11. GRIMM, L. M., GOLDBERG, A. L., POIRIER, G. G., SCHWARTZ, L. M. & OSBORNE, B. A. (1996). Proteasomes play an essential role in thymocyte apoptosis. EMBO Journal 1, 3835-3844.
12. KISSELEV, A. F. & GOLDBERG, A. L. (2001). Proteasome inhibitors: from research tools to drug candidates. Chemistry and Biology 8, 739-758.
13. KOTHAKOTA, S., AZUMA, T., REINHARD, C., KLIPPEL, A., TANG, J., CHU, K., MCGARRY, T. J., KIRSCHNER, M. W., KOTHS, K., KWIATKOWSKI, D. J. & WILLIAMS, L. T. (1997). Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278, 294-298.
14. KOZLOWSKI, L., STOKLOSA, T., OMUKA, S., WOJCIK, C., WOJTUKIEWICZ, M. Z., WOROWSKI, K. & OSTROWSKA, H. (2001). Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biology 22, 211-215.
15. KRNAJSKI, Z., WALTER, R. D. & MULLER, S. (2001). Isolation and functional analysis of two thioredoxin peroxidases (peroxiredoxins) from Plasmodium falciparum. Molecular and Biochemical Parasitology 113, 303-308.
16. LANG, K. S., DURANTON, C., POEHLMANN, H., MYSSINA, S., BAUER, C., LANG, K., WIEDER, T. & HUBER, S. M. (2003). Cation channels trigger apoptotic death of erythrocytes. Cell Death and Differentiation 10, 249-256.
17. LJUNGSTRÖM, I., PERLMANN, H., SCHLICHTERLE, M., SCHERF, A. & WAHLGREN, M. (2004). Methods in Malaria Research, 4th Edn. MR4/ATCC, Manassas, Virginia.
18. MUTOMBA, M. C., TO, W. Y., HYUN, W. C. &. WANG, C. C. (1997). Inhibition of proteasome activity blocks cell cycle progression at specific phase boundaries in African trypanosomes. Molecular and Biochemical Parasitology 90, 491-504.
19. NOEDL, H., WERNSDORFER, W. H., MILLER, R. S. & WONGSRICHANALAI, C. (2002). Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrobial Agents and Chemotherapy 46, 1658-1664.
20. NOEDL, H., WONGSRICHANALAI, C. & WERNSDORFER, W. H. (2003). Malaria drug-sensitivity testing: new assays, new perspectives. Trends in Parasitology 19, 175-181.
21. ORLOWSKI, R. Z., STINCHCOMBE, T. E., MITCHELL, B. S., SHEA, T. C., BALDWIN, A. S., STAHL, S., ADAMS, J., ESSELTINE, D. L., ELLIOTT, P. J., PIEN, C. S., GUERCIOLINI, R., ANDERSON, J. K., DEPCIK-SMITH, N. D., BHAGAT, R., LEHMAN, M. J., NOVICK, S. C., O'CONNOR, O. A. & SOIGNET, S.-L. (2002). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology 20, 4420-4427.
22. STEFANELLI, C., BONAVITA, F., STANIC, I., PIGNATTI, C., FARRUGGIA, G., MASOTTI, L., GUARNIERI, C. & CALDARERA, C. M. (1998). Inhibition of etoposide-induced apoptosis with peptide aldehyde inhibitors of proteasome. The Biochemical Journal 332, 661-665.
23. TRAGER, W. (1971). A new method for intraerythrocytic cultivation of malaria parasites (Plasmodium coatneyi and P. falciparum). Journal of Protozoology 18, 239-242.
24. VOORHEES, P. M., DEES, E. C., O'NEIL, B. & ORLOWSKI, R. Z. (2003). The proteasome as a target for cancer therapy. Clinical Cancer Res. 9, 6316-6325.
25. WORLD HEALTH ORGANIZATION (2001). Drug Resistance in Malaria. CSR Resources WHO, Geneva.